Eloxx Pharmaceuticals, Inc. Research and Development in Process
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-03-31
- Eloxx Pharmaceuticals, Inc. research and development in process for the quarter ending 2022-12-31 was $0.00.
- Eloxx Pharmaceuticals, Inc. research and development in process for the quarter ending 2022-09-30 was $0.00.
- Eloxx Pharmaceuticals, Inc. research and development in process for the quarter ending 2021-12-31 was $0.00.
- Eloxx Pharmaceuticals, Inc. research and development in process for the quarter ending 2021-09-30 was $0.00.
- Eloxx Pharmaceuticals, Inc. research and development in process for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Eloxx Pharmaceuticals, Inc. research and development in process for fiscal 2021 was $22.67M.
| Period end | Research and Development in Process 3 month | Research and Development in Process 6 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | $0.00 10-K · filed 2023-03-31 | |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | $22.67M derived: sum of 3 quarters · filed 2023-03-31 | $22.67M 10-K · filed 2023-03-31 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-10 | $22.67M derived: sum of 2 quarters · filed 2022-11-10 | $22.67M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $22.67M 10-Q · filed 2022-08-12 | $22.67M 10-Q · filed 2022-08-12 |